ArticleFrontiers in cardiovascular medicine2026
Association of estimated pulse wave velocity with outcomes following drug-coated balloon therapy in elderly coronary artery disease patients.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Drug-coated balloons (DCBs) constitute a vital therapeutic approach in the interventional management of coronary heart disease. Nevertheless, the risk factors for predicting target lesion revascularization (TLR) and major adverse cardiovascular events (MACE) specifically within the elderly population following DCB angioplasty remain incompletely understood. The study is to explore the relationship between estimated pulse wave velocity (ePWV) values and the risk of TLR and MACE in elderly patients undergoing DCB treatment, and to explore the optimal ePWV cutoff for clinical risk stratification. Methods: A total of 423 participants were stratified into quartiles based on their ePWV values. Baseline characteristics were compared among these quartiles. The associations between ePWV and the risk of TLR and MACE were evaluated using Cox regression models, adjusted for multiple covariates. Kaplan-Meier analysis with the log-rank test was utilized to assess survival differences. The optimal ePWV cutoff for risk stratification was identified through maximally selected rank statistics. Subgroup analyses were performed to examine interactions between ePWV and clinical variables. Results: Differences emerged across ePWV quartiles for age, TLR, and MACE (all Conclusion: Elevated ePWV was associated with a higher risk of TLR and MACE. An exploratory cutoff for ePWV at 10.91 m/s was identified, stratifying patients into distinct clinical risk groups.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.